Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET.
賓夕法尼亞州康沃霍肯，2024年8月26日（環球新聞社）- madrigal pharmaceuticals公司（納斯達克：MDGL）今日宣佈，公司將參加摩根士丹利第22屆年度全球醫療保健大會，時間爲2024年9月5日上午10:45。
The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events page. A replay of the webcast will be available after the event.
演示將通過網絡直播，可在此處或訪問Madrigal的投資者關係活動頁面進行訪問。活動結束後將提供網絡直播的重播。
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit .
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc.（納斯達克股票代碼：MDGL）是一家生物製藥公司，致力於開發新型非酒精性脂肪肝（NASH）治療藥物，這是一種急需醫療援助的肝臟疾病。Madrigal的藥物Rezdiffra（resmetirom）是一種每日一次的口服、以肝臟爲靶向的THR-β激動劑，旨在針對NASH的一些關鍵原因。欲了解更多信息，請訪問。
Investor Contact
Tina Ventura, [email protected]
投資者聯繫方式
Tina Ventura，[email protected]
Media Contact
Christopher Frates, [email protected]
媒體聯繫人
Christopher Frates，[email protected]
Source: Madrigal Pharmaceuticals, Inc.
消息來源：Madrigal製藥公司
譯文內容由第三人軟體翻譯。
